In this study, with a median follow-up of 25 months, the primary composite end point including cardiovascular death, MI, stroke, and hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (HR, 1.02
Our healthcare providers carefully evaluate each patients health profile to determine the most suitable treatment plan, always prioritizing safety and efficacy
1-888-204-4062 (TTY: 711) See plans in your area Enter your ZIP code below to see plans with their premiums, copays, and participating doctors and pharmacies
doi: 10.3389/fendo.2021.645563
Professional advice, great for international patient
Visible changes in body composition and clothing fit are common by this point